PORT WASHINGTON, NY – February 27, 2018 – Pall Corporation, a global leader in filtration, separation and purification, has opened an expanded Hoegaarden office after eight months of construction. A ribbon-cutting ceremony held in early December was attended by Pall leadership, local government officials, and Zaventem and Brussels associates.
 

The Hoegaarden facility expansion includes 2,000 m² (over 21,000 sq. ft) of new office space providing work stations for 100 employees, in addition to new research and development, customer demonstration labs and manufacturing space. Three Belgian locations have been combined into the one location, bringing headcount in the Hoegaarden office to over 300 full- time equivalent employees.
 

“The expanded Hoegaarden site has it all: offices, labs and manufacturing space for development and optimization of customer processes. With this site, we will be better equipped to provide whole service to customers in the area, while supporting the local economy,” Mario Philips, Vice President and General Manager of Pall Biotech said. “In this new space, we have consolidated three Pall Belgian offices as one, which is why we have designated Hoegaarden as a hub of strategic importance for our future growth.”
 

Mario Philips and Raf Vanheel, Pall Hoegaarden's Plant Manager, were joined by Hoegaarden City Mayor Jean-Pierre Taverniers and City Counselor Hans Decoster to commemorate the official opening of the building.

To learn more about the full portfolio of products and services, please visit: www.pall.com/biotech. Or to start a conversation with our team, and learn how we might be able to support your next level of success, email: biotech@pall.com
 

About Pall Corporation

Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide.


For more information visit www.pall.com.
 

Or follow us on social media: Google+ - YouTube -   LinkedIn - Twitter - Facebook

 

Corporate Media Contact

Pall Corporation

Mariann Kourafas

Director of Communications

+1-508-871-5469
 

Media Contact

White Matter Communications

Beth Willers

bethw@whitemattercomm.com

+1-415-905-0324

More Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
July 2019
July 16, 2019: Servier chooses Pall as exclusive technology and services provider for planned Bio-S biomanufacturing facility in France
April 2019
April 29, 2019: Freeline's (AAV) manufacturing platform and Pall’s iCELLis bioreactor system combine to achieve commercial-scale and high quality production of AAV gene therapy vectors
March 2019
March 19, 2019: New lab will serve as a dedicated platform where the industry can access shared resources including equipment, expertise and project work to find innovative solutions to manufacturing needs for biologic medicines, such as cell-based immunotherapies
March 13, 2019: Pall Biotech to distribute ARTeSYN’s standard hardware and liner components for fluid flow control. Customers to benefit from the flexibility, agility and reliability required for their bioprocessing journey, with accelerated implementation of robust and standardized single-use fluid management and control
March 11, 2019: Pall Biotech to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors; sensor will be integrated into Pall Biotech’s single-use technologies
December 2018
December 18, 2018: New centre to give Pall customers options ranging from batch to single use and continuous bioprocessing solutions, and to provide technology solutions that meet current needs, while offering some of the most progressive technological solutions for the future
November 2018
November 26, 2018: Cobra and Pall to make commercialisation of gene therapies safer, faster, and cheaper than ever before, help increase patient access to gene therapy and further establish best practices in manufacturing
October 2018
October 2, 2018: New centre will work to enhance drug production and empower the future workforce, reinforcing Pall's commitment to continuously improve bioprocesses through strategic partnerships
September 2018
September 24, 2018: New collaboration to see G-CON PODs customized with Pall technologies, addressing customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing
September 11, 2018: Pall and Aetos partner to combine bioreactors, mixing and storage, and downstream technologies with cell lines and manufacturing processes for expedited biosimilars development